Cadila Healthcare announced that the company's API manufacturing facility located at Dabhasa, Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 7 to 11 October 2019. The EIR report stated that the
classification of the facility is 'No Action Indicated (NAI)'.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
